Philip Beer

Philip Beer currently serves as the Chief Scientific Officer and Vice President, Head of Research and Translational Medicine at Step Pharma since July 2021, focusing on developing novel therapeutics targeting CTP Synthase 1. Additionally, Philip holds the position of Honorary Professor in Translational Medicine at Hull York Medical School and chairs the Genomics Working Group for the British In Vitro Diagnostics Association. With extensive experience in clinical cancer genomics, including supporting major genomic projects and serving as a Consultant Haematopathologist, Philip has also founded Gabriel Precision Oncology and collaborates with institutions like Mayo Clinic and Wellcome Sanger Institute on cancer research. Previous roles include Head of Research and Translational Medicine at Karus Therapeutics and participation in various cancer clinical and research initiatives. Philip earned degrees from the University of Cambridge and the University of Nottingham, while also being associated with prestigious professional bodies such as the Royal College of Pathologists and the Royal College of Physicians.